EnBiotix has in-licensed ColiFin® from PARI Pharma GmbH, a global leader in nebulized therapies, for worldwide rights ex-Europe. Approved in Europe since 2010 as a front-line therapy for lung infections in CF, ColiFin® has a proven safety and efficacy track record which EnBiotix is leveraging initially towards the U.S. market.
ColiFin for Cystic Fibrosis Lung Infections
Advantages of ColiFin®:
- Acts via different mechanism of action versus other approved inhaled antibiotics
- Significantly lower rate of resistance
- No cross-resistance with other classes
- Further enables altnernating & combination CF antibiotic therapy
Bridging ColiFin® EU Approval to US CF Standard-of-Care: